Score of inattention subscale of ADHD rating scale-IV is significantly higher for AD/HD than PDD.

نویسندگان

  • Hiromi Fujibayashi
  • Shinji Kitayama
  • Masafumi Matsuo
چکیده

Attention-deficit/hyperactivity disorder (AD/HD) and pervasive developmental disorder (PDD) must be differentiated because the respective treatments are different. However, they are difficult to distinguish because they often show similar symptoms. At our hospital, we have the rearer of a patient answer both the ADHD Rating Scale-IV (ADHD-RS) and the Autism Spectrum Screening Questionnaire (ASSQ), and use the results as an aid for the diagnosis of AD/HD or PDD. These results were compared with reference to PDD and AD/HD for an examination of the features of the two disorders. The subjects of our study were 45 children with AD/HD and 77 children with PDD. ADHD-RS score was significantly higher for AD/HD than PDD, but the total ASSQ score was significantly higher for PDD than AD/HD. Furthermore, for the inattention subscale of ADHD-RS, both total score and number of high-score items were significantly higher for AD/HD than PDD. As for the ASSQ score for PDD, it was significantly higher than for AD/HD in the domains of repetitive behavior, social interaction, and communication problems. In addition, PDD features many high-score items in the social interaction domain. We thought that these results about both ADHD-RS and ASSQ were useful for the differentiation of AD/HD or PDD.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Ginkgo biloba in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. A randomized, placebo-controlled, trial.

OBJECTIVE To evaluate the efficacy of Ginkgo biloba as a complementary therapy for attention-deficit/hyperactivity disorder (ADHD). METHODS Children and adolescents with ADHD received methylphenidate (20-30 mg/day) plus either G. biloba (80-120 mg/day) or placebo for 6 weeks. Parent and teacher forms of the ADHD Rating Scale-IV (ADHD-RS-IV) were completed at baseline, week 2, and week 6. Trea...

متن کامل

Reliability and Validity of Parent and Teacher Ratings of Attention-deficit/hyperactivity Disorder Symptoms

The reliability and criterion-related validity of the Home and School versions of the AD/HD Rating Scale-IV were evaluated in a nonreferred sample of 71 students. Parent and teacher ratings were obtained 4 weeks apart at a time contemporaneous with observations of classroom behavior and academic productivity. Results indicated adequate levels of internal consistency, test-retest reliability, an...

متن کامل

Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study.

OBJECTIVE This pilot study examined the effects of atomoxetine on attention-deficit/hyperactivity disorder (ADHD) symptoms and autistic features in children with pervasive developmental disorders (PDD). METHOD Twelve children (aged 6-14 years) with PDD accompanied by ADHD symptoms entered a 10-week open-label study with atomoxetine (1.19 +/- 0.41 mg/kg/day). Response was assessed by using par...

متن کامل

Seasonal Variations in the Severity of ADHD Symptoms in the Dutch General Population.

OBJECTIVE This is the first study to examine self-reported seasonal differences in the severity of ADHD symptoms in adults from the general population. METHOD Data were analyzed from N = 5,303 respondents participating in the second wave of the Netherlands Mental Health Survey and Incidence Study-2, a population-based study on mental health. ADHD symptoms were assessed using the Adult ADHD Se...

متن کامل

Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder.

OBJECTIVE This study examined the efficacy and safety of clonidine hydrochloride extended-release tablets (CLON-XR) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD). METHOD This 8-week, placebo-controlled, fixed-dose trial, including 3 weeks of dose escalation, of patients 6 to 17 years old with ADHD evaluated the efficacy and safety of CLON-XR 0.2 mg/day or CL...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • The Kobe journal of medical sciences

دوره 56 1  شماره 

صفحات  -

تاریخ انتشار 2010